Chemours Q1 earnings: net sales $1.35B (-12% YoY), net income $52M, adj EBITDA $193M

Chemours Co

2024-Q1 EPS reported $0.34 revenue$1,350,000,000

Net sales $1.35B, down 12% YoY; volumes -6%, price -5%.
Net income attributable to Chemours $52M ($0.34 per diluted share) vs $145M ($0.96) in Q1 2023.
Adjusted EBITDA $193M vs $304M (-37%).
Cash flows used in operations -$290M; capex $102M; dividends $37M.
Segment declines: APM -23%, TT -7%, TSS -8%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Chemours Co reported first quarter 2024 results: revenue $1.4 billion, net income $52 million, or $0.34 per diluted share, EPS $0.34 per diluted share.

Period: first quarter 2024
Revenue: $1.4 billion
Net income: $52 million, or $0.34 per diluted share
EPS: $0.34 per diluted share
Result: reported results

Exact text from the filing

Solutions (“TSS”), and Advanced Performance Materials (“APM”), today announced its financial results for the first quarter 2024. Key First Quarter 2024 Results • Net Sales of $1.4 billion, down 12% year-over-year • Net Income attributable to Chemours of $52 million, or $0.34 per diluted share, compared with $145 million, or $0.96 per diluted share, in the

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Chemours Co filing history →

Source: SEC EDGAR

accession 0000950170-24-050569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.